Last reviewed · How we verify
Silapo (EPOETIN ZETA)
Silapo (generic name: EPOETIN ZETA) is a Recombinant protein drug developed by Hospira UK Limited. It is currently FDA-approved (first approved 2007) for Anemia in chronic kidney disease.
At a glance
| Generic name | EPOETIN ZETA |
|---|---|
| Sponsor | Hospira UK Limited |
| Target | Erythropoietin receptor |
| Modality | Recombinant protein |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 2007 |
Approved indications
- Anemia in chronic kidney disease
Common side effects
Key clinical trials
- Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia
- Biological Predictive Factors of Response to ESA in Low Risk MDS Patients (PHASE4)
- Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology
- Erythropoietin (EPO) to Protect Renal Function After Cardiac Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Silapo CI brief — competitive landscape report
- Silapo updates RSS · CI watch RSS
- Hospira UK Limited portfolio CI
Frequently asked questions about Silapo
What is Silapo?
Silapo (EPOETIN ZETA) is a Recombinant protein drug developed by Hospira UK Limited, indicated for Anemia in chronic kidney disease.
What is Silapo used for?
Silapo is indicated for Anemia in chronic kidney disease.
Who makes Silapo?
Silapo is developed and marketed by Hospira UK Limited (see full Hospira UK Limited pipeline at /company/hospira-uk-limited).
What is the generic name of Silapo?
EPOETIN ZETA is the generic (nonproprietary) name of Silapo.
When was Silapo approved?
Silapo was first approved on 2007.
What development phase is Silapo in?
Silapo is FDA-approved (marketed).
What does Silapo target?
Silapo targets Erythropoietin receptor.
Related
- Target: All drugs targeting Erythropoietin receptor
- Manufacturer: Hospira UK Limited — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Anemia in chronic kidney disease
- Compare: Silapo vs similar drugs
- Pricing: Silapo cost, discount & access